您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报(医学版) ›› 2017, Vol. 55 ›› Issue (11): 80-84.doi: 10.6040/j.issn.1671-7554.0.2016.1630

• 公共卫生与管理学 • 上一篇    下一篇

亚太地区部分国家老年人慢性病基本药物的价格和可及性

蒋梦雅1,娄红祥1,孙强2,王海鹏2   

  1. 1.山东大学药学院, 山东 济南 250012;2.山东大学医药卫生管理学院 国家卫生与计划生育委员会卫生经济与政策研究重点实验室(山东大学), 山东 济南 250012
  • 收稿日期:2016-12-07 出版日期:2017-11-10 发布日期:2017-11-10
  • 通讯作者: 孙强. E-mail:qiangs@sdu.edu.com E-mail:qiangs@sdu.edu.com
  • 基金资助:
    山东大学基本科研业务费自助项目国际合作项目(2015GJ10)

Price and the accessibility of essential medicines for the elderly with chronic diseases in the Asia Pacific Region

JIANG Mengya1, LOU Hongxiang1, SUN Qiang2, WANG Haipeng2   

  1. 1. School of Pharmacy, Shandong University, Jinan 250012, Shandong, China;
    2. School of Health Care Management, Key Laboratory for Health Economic and Policy of National Health and Family Planning Commission, Shandong University, Jinan 250012, Shandong, China
  • Received:2016-12-07 Online:2017-11-10 Published:2017-11-10

摘要: 目的 了解老年人慢性病基本药物在亚太地区6个国家的价格及可及性现状,为提高老年人慢性病基本药物的可及性提供依据和政策建议。方法 〓采用二手资料分析法,从WHO/HAI调查数据中提取相关药品数据,根据通货膨胀/通货紧缩和购买力平价转化数据。 结果 6个国家公立机构老年人慢性病基本药物通用药及原研药的可获得性分别为5.0%~80.0%、1.8%~15.4%,私立机构通用药及原研药可获得性分别为11.7%~54.5%、10.0%~65.6%;公立机构通用药及原研药的可负担性分别为0~1.2倍、0~5.0倍日薪,私立机构通用药及原研药的可负担性分别为0.3~2.0倍、1.2~7.0倍日薪;公立机构通用药及原研药的零售中位价格比(MPR)分别为0~32.88、0~79.13,私立机构通用药及原研药的的零售MPR分别为0.92~46.21、13.84~103.75。 结论 6个国家老年人慢性病用药可获得性较低,药品价格高于国际水平,药品可负担性整体较差;6个国家的老年人慢性病基本药物的可及性有待提高。

关键词: 价格, 可及性, 亚太地区, 慢性病基本药物

Abstract: Objective To study the price and accessibility of essential medicines for the elderly with chronic diseases in the six countries of Asia Pacific, and to provide evidence and policy recommendations. Methods The secondary data, which were adjusted according to the inflation/deflation, were acquired from the researches of WHO/HAI and analyzed. Results The availability values of lowest price generic and originator brand in public hospital in the six countries were 5.0%-80.0% and 1.8%-15.4%, while those in private hospital were 11.7%-54.5% and 10.0%-65.6%. The affordability values of lowest price generic and originator brand in public hosipital were 0-1.2 and 0-5.0 times of daily wages, while those in private hospital were 0.3-2.0 and 1.2-7.0 times of daily wages. The median price ratios(MPRs)of lowest price generic and originator brand in public hospital were 0-32.88 and 0-79.13, while those in private hospital were 0.92-46.21 and 13.84-103.75. Conclusion The availability of essential medicines for chronic diseases in the six countries is low, the price of the medicines is higher than the international reference price, and the affordability of the medicine is poor. The accessibility of the medicine must be improved.

Key words: Essential medicines for chronic diseases, Accessibility, Asia Pacific Region, Price

中图分类号: 

  • R956
[1] World Health Organization. Regional framework for action on ageing and health in the Western Pacific(2014-2019)[EB/OL].(2014)[2016-12-07]. http://iris.wpro.who.int/bitstream/handle/10665.1/10422/9789290616566_eng.pdf.
[2] 陆慧敏.人口老龄化与老年人口健康及疾病问题的研究进展[J].世界最新医学信息文摘, 2016, 16(4): 39-40.
[3] WHO, HAI. Medicine prices: a new approach to measurement. Working draft for field testing and revision[EB/OL].(2010-03-01)[2016-12-07]. http://www.haiweb.org/medicineprices/manual/manuals/MedicinePrices.pdf.
[4] 管晓东,史录文.基于WHO/HAI标准调查法的我国基本药物可及性评价方法研究[J].中国药房, 2013, 24(24): 2212-2215. GUAN Xiaodong, SHI Luwen. Study on evaluation method for the accessibility of essential medicine in China based on WHO/HAI standardized approach[J]. China Pharmacy, 2013, 24(24): 2212-2215.
[5] 李萍,王迪飞,吕景睿,等.标准化药品价格调查法及其在我国应用的思考[J].医学与社会, 2010, 23(3): 33-35. LI Ping, WANG Difei, LÜ Jingrui, et al. The methodology of investigation of standardization of drug price and use for reference[J]. Medicine and Society, 2010, 23(3): 33-35.
[6] Frye JE. International drug price indicator guide[EB/OL].(2012)[2016-12-07]. http://www.msh.org/sites/msh.org/files/international-drug-price-indicator-guide.pdf.
[7] Gelders S, Ewen M, Noguchi N, et al. Price, availability and affordability: an international comparison of chronic disease medicines[EB/OL].(2006)[2016-12-07]. http://apps.who.int/iris/bitstream/10665/116493/1/dsa560.pdf.
[8] 罗莎,马爱霞.WHO/HAI药品价格评价及应用介绍[J].中国药物经济学, 2010(5): 73-80.
[9] Comparing price data from different surveys[EB/OL].(2007)[2016-12-07]. http://www.haiweb.org/medicineprices/manual/comparing.html.
[10] Batangan DB, Echavez C, Santiago A, et al. The prices people have to pay for medicines in the Philippines[EB/OL].(2005)[2016-12-07]. http://www. haiweb. org/medicineprices/surveys/200502PH/sdocs/survey_report. pdf.
[11] Nguyen AT, Knight R, Mant A, et al. Medicine prices, availability, and affordability in Vietnam[J]. Southern Med Review, 2009, 2(2): 2-9.
[12] Babar ZUD, Ibrahim MIN, Singh H, et al. A survey of medicine prices, availability, affordability and price components in Malaysia using the who/hai Methodology[EB/OL].(2005-10)[2016-12-07]. https://www.researchgate.net/publication/274962435_A_SURVEY_OF_MEDICINE_PRICES_AVAILABILITY_AFFORDABILITY_AND_PRICE_COMPONENTS_IN_MALAYSIA_USING_THE_WHOHAI_METHODOLOGY.
[13] Fang Y. Medicine prices, availability and affordability in Shaanxi Province, western China[EB/OL].(2012-09)[2016-12-07]. http://www.haiweb.org/medicineprices/13082013/2010_survey_report_shaanxi.pdf.
[14] 武丽娜,魏德宏,陈琛,等.陕西省基层医疗卫生机构基本药物制度实施效果评估研究[J].中国药事, 2014, 28(11): 1173-1177. WU Lina, WEI Dehong, CHEN Chen, et al. Study on the implementation of essential medicine policy in primary care institutions in Shaanxi Province[J]. Chinese Pharmaceutical Affairs, 2014, 28(11): 1173-1177.
[15] 姜明欢,王乐,王文娟,等.陕西省公立医院基本药物制度实施状况评估[J].中华医院管理杂志, 2013, 29(5): 347-352. JIANG Minghuan, WANG Le, WNAG Wenjuan, et al. Assessment of the implementations of the essential medicine policy in public hospitals in Shaanxi Province[J]. Chin J Hosp Admin, 2013, 29(5): 347-352.
[16] 袁泉,邵蓉.基本药物可获得性障碍研究[J].上海医药, 2010, 31(3): 116-118.
[17] 吴建华,刘萍,吴东方,等.基于国外经验的基本药物可获得性和可及性探讨[J].中国药房, 2011, 22(20): 1833-1835. WU Jianhua, LIU Ping, WU Dongfang, et al. Investigation of the availability and accessibility of essential drugs based on experience abroad[J]. China Pharmacy, 2011, 22(20): 1833-1835.
[18] Sun Q. A survey of medicine prices, availability, affordability and price components in Shandong Province, China contents[EB/OL].(2005-10-01)[2016-12-07] http://www.haiweb.org/medicineprices/surveys/200411CN/survey_report.pdf.
[19] Lu YE. A survey of medicine prices, availability and affordability in Shanghai, China using the WHO/HAI methodology[EB/OL].(2006-12-01)[2016-12-07]. http://haiweb.org/wp-content/uploads/2015/07/China-Shanghai-Report-Pricing-Surveys.pdf.
[20] Yang H, Dib HH, Zhu M. Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China[J]. Health Policy Plan, 2010, 25(3): 219-229.
[21] 徐伟,殷丹妮.江苏省基本药物可负担性实证研究[J].上海医药, 2012, 33(3):43-47. XU Wei, YIN Danni. Evidence-base study on the affordability of essential medicines in Jiangsu Province[J]. Shanghai Medical & Pharmaceutical Journal, 2012, 33(3): 43-47.
[22] 李萍,吕景睿,阳昊,等.湖北省农村居民基本药物可负担性研究[J].医学与社会, 2010, 23(2): 18-20. LI Ping, LÜ Jingrui, YANG Hao, et al. Study on the affordablity of essential medicines in rural areas of Hubei Province[J]. Medicine and Society, 2010, 23(2): 18-20.
[23] 徐伟,殷丹妮.我国基本药物可负担性实证研究[J].中国药房, 2012(40): 3745-3747. XU Wei, YIN Danni. Empirical study on the affordability of essential drugs in China[J]. China Pharmacy, 2012(40): 3745-3747.
[24] Thomas R, Vitry A. Consumers perception of generic medicines in community pharmacies in Malaysia[J]. South Med Rev, 2009, 2(2): 20-23.
[25] 蒋华,刘涛,陈文芳.社区老年人用药安全现状及对策研究[J].中国实用护理杂志, 2011, 27(28): 64-65.
[26] Chuc NT, Larsson M, Do NT, et al Improving private pharmacy practice: a multiintervention experiment in Hanoi, Vietnam[J]. J Clin Epidemiol, 2002, 55(11): 1148-1155.
No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!